View as an RSS Feed
View Wall Street Titan's Articles BY TICKER:
GoPro Weak First Quarter - What Investors Are Missing
- 60 Minutes Profile in November 2013 Should Have Been a Marketing Bonanza.
- The Red Flag: Why Did Sales Fall in First Quarter 2014?
- Is GoPro Sales Momentum Already Running Out of Steam?
Athersys: Down But Not Out - An Interview With CEO Van Bokkelen
- Shares Battered After Failure to Show Efficacy in Ulcerative Colitis (UC) Phase II.
- CEO Van Bokkelen Answers the Tough Questions Including: Why No Recent Insider Buying?
- The Science Behind Multistem Stroke Therapy.
- Efficacy in Stroke Trial Unleashes Tremendous Value.
Cytori Therapeutics Announces Date For Crucial BARDA Meeting
- Company States it Has Met The Three Required Objectives to Move Forward.
- Next Phase of BARDA Contract is Worth $56,000,000.
- Success Would Put The Company on Path To Fully Financed FDA Approval.
Fuel Cell Energy Reality Check: A Valuation Comparison To First Solar
- Fuel Cell Energy and First Solar compete in the same space: distributed generation.
- We do a valuation comparison of the two companies based on sales, gross profit and book value.
- Analysis reveals FCEL is unsustainably overvalued in comparison to First Solar.
Mandalay Digital: Arms Supplier To Mobile Monetization Wars Poised For Explosive Growth
- Net Neutrality Wars Also Apply To Mobile Handset Market.
- Mandalay Digital Has Created An Arsenal to Help Wireless Carriers Capture Revenues.
- Verizon Wireless Ramp Up This Summer Should Be the Inflection Point.
Fuel Cell Energy By The Numbers
- PLUG Power's recent sales to Walmart have no bearing on the business of Fuel Cell Energy.
- Fuel Cell Energy's Product backlog has been in decline.
- Fuel Cell's gross margins remain weak.
- Cytori Therapeutics: Global Patient Stem Cell Demand Builds, Important Short-Term Catalysts Ahead
- Athersys: Why Did Shareholders Come Knocking At The Door Once Again?
- Time To Sell Apollo Commercial Real Estate Finance
- Ramifications Of New Japanese Stem Cell Legislation Are Unappreciated By Investors
- China Green Agriculture - The Rodney Dangerfield Of Fertilizer?
- Cytori Therapeutics $531,000,000 Agreement - Money Talks
- Cytori Therapeutics - Independent Study On Scleroderma Shows Great Results
- Goldman Sachs, National Grid And The Tale Of 2 Auction Rate Securities
- Apollo Commercial Real Estate Finance - The Goldilocks Yield Play For Today's Environment?
- SalesForce.com: A Case For Adding Back Stock-Based Compensation
- North Korean Threats And The Cytori - BARDA Stem Cell Collaboration
- Cytori's EU Approval For Intravase - Intentionally Downplayed?
- Worth The Wait: Implications Of Cytori Therapeutics' $106 Million BARDA Contract
- Merge Healthcare Puts Itself Up For Sale
- Osiris Stem Cell Drug Approval Bodes Well For Athersys
- With Cytori Therapeutics, The Waiting Is The Hardest Part
- China Green Agriculture Shares Poised To Move Higher
- New Okyanos Heart Institute Makes Big Bet On Cytori Therapeutics Technology
- Heavyweight Valuation Matchup: Salesforce.com Vs. Apple Vs. Google
- China Green Agriculture: Super EPS, Raising Guidance
- Concur Technologies: Will The Real EPS Numbers Please Stand Up
- Follow The Money: Insider Purchases At Merge Healthcare Make It Attractive
- European Scandal Could Help Cytori Therapeutics
- Concur Technologies Priced Past Perfection
- Athersys Shares Poised To Move Higher
- China Green Agriculture Reports Record Earnings But Can It Regain Its Credibility?